{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:08:53Z","timestamp":1784326133403,"version":"3.55.0"},"reference-count":27,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008207","name":"AstraZeneca Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008207","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Current Oncology"],"abstract":"<jats:p>First-line options for chronic lymphocytic leukemia (CLL) are evolving, recently returning to a fixed-duration (FD) approach incorporating regimens such as venetoclax + obinutuzumab, ibrutinib + venetoclax, and soon acalabrutinib + venetoclax \u00b1 obinutuzumab. Five Canadian hematologists convened to share perspectives regarding the attributes of these options and considerations for clinically appropriate integration within Canada\u2019s publicly funded healthcare system. The hematologists underscored the importance of shared decision-making with patients, family members, and caregivers involving careful consideration of disease profile and patient characteristics, preferences, and values. They indicated that although a role persists for continuous therapy with approved covalent Bruton\u2019s tyrosine kinase inhibitors (typically in high-risk disease), newer FD regimens offer multiple benefits related to the treatment-free period, quality of life, safety, re-treatment, healthcare resource utilization, and costs. The hematologists highlighted the appeal of all-oral FD combinations given their convenience and impact on treatment equity, factors especially compelling given Canada\u2019s vast geography and large segment of rural populations. In closing, they emphasized the quickly evolving therapeutic setting of CLL in the 1L and beyond, underscoring the need for ongoing patient involvement in decision-making to support optimal treatment selection based on patient goals and within the confines of provincial funding.<\/jats:p>","DOI":"10.3390\/curroncol32100543","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:01:39Z","timestamp":1759154499000},"page":"543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contemporary Fixed-Duration Treatment Options in the First-Line Setting of Chronic Lymphocytic Leukemia: Perspectives from a Publicly Funded Healthcare System"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0281-5866","authenticated-orcid":false,"given":"Christopher","family":"Lemieux","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Centre Int\u00e9gr\u00e9 de Canc\u00e9rologie, CHU de Qu\u00e9bec-Universit\u00e9 Laval, 2250 Boul. Henri-Bourassa, Qu\u00e9bec City, QC G1J 0J9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3311-9169","authenticated-orcid":false,"given":"Chai W.","family":"Phua","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Western University, 800 Commisioners Road East, London, ON N6A 5W9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Sue","family":"Robinson","sequence":"additional","affiliation":[{"name":"Division of Hematology, QEII Health Sciences Centre, Dalhousie University, 1247 South Park Street, Halifax, NS B3H 2Y9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Owen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematological Malignancies, Arthur J.E. Child Comprehensive Cancer Centre, 3395 Hospital Drive NW, Calgary, AB T2N 5G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7415-8818","authenticated-orcid":false,"given":"Versha","family":"Banerji","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Biochemistry and Maedical Genetics, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, CancerCare Manitoba, 750 Bannatyne Avenue, Winnipeg, MB R3E 0T4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107372","DOI":"10.1016\/j.leukres.2023.107372","article-title":"Canadian evidence-based guideline for treatment of relapsed\/refractory chronic lymphocytic leukemia","volume":"133","author":"Owen","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.2023020158","article-title":"Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up","volume":"142","author":"Thompson","year":"2023","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): A randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"TPS7087","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7087","article-title":"CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na\u00efve (TN) CLL","volume":"42","author":"Shadman","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_16","unstructured":"Statistics Canada (2025, May 12). Population Estimates: Key Indicators. Quarterly Population Estimate (1 January 2025). Available online: https:\/\/www150.statcan.gc.ca\/n1\/en\/subjects\/population_and_demography\/population_estimates."},{"key":"ref_17","unstructured":"Statistics Canada (2025, May 12). Focus on Geography Series, 2021 Census of Population: Canada. Available online: https:\/\/www12.statcan.gc.ca\/census-recensement\/2021\/as-sa\/fogs-spg\/page.cfm?lang=E&topic=1&dguid=2021A000011124."},{"key":"ref_18","unstructured":"Health Canada (2025, May 12). Product Monograph Including Patient Medication Information. IMBRUVICA (Ibrutinib). Available online: https:\/\/pdf.hres.ca\/dpd_pm\/00070123.PDF."},{"key":"ref_19","unstructured":"Health Canada (2025, May 12). Product Monograph Including Patient Medication Information. VENCLEXTA (Venetoclax). Available online: http:\/\/pdf.hres.ca\/dpd_pm\/00065382.PDF."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Robrecht","year":"2024","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1200\/JCO.2024.42.16_suppl.7009","article-title":"Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study","volume":"42","author":"Wierda","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1158\/1078-0432.CCR-23-2872","article-title":"Overcoming resistance in chronic lymphocytic leukemia-maybe less is more?","volume":"30","author":"Davids","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","article-title":"Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax","volume":"30","author":"Jain","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2023-174750","article-title":"Acalabrutinib \u00b1 obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 6-year follow-up of ELEVATE-TN","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus bendamustine and rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: Median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1158\/1078-0432.CCR-22-0504","article-title":"Effective tumor debulking with ibrutinib before initiation of venetoclax: Results from the CAPTIVATE minimal residual disease and fixed-duration cohorts","volume":"28","author":"Barr","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T04:38:37Z","timestamp":1759207117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,28]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["curroncol32100543"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32100543","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,28]]}}}